Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stake Boosted by Rhumbline Advisers

Rhumbline Advisers grew its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 125.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 55,723 shares of the company’s stock after acquiring an additional 31,056 shares during the period. Rhumbline Advisers’ holdings in Lifecore Biomedical were worth $414,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Creative Planning acquired a new position in shares of Lifecore Biomedical during the third quarter worth approximately $69,000. ARS Investment Partners LLC bought a new stake in shares of Lifecore Biomedical during the fourth quarter valued at approximately $74,000. Public Employees Retirement System of Ohio bought a new stake in shares of Lifecore Biomedical during the third quarter valued at approximately $119,000. Barclays PLC grew its position in Lifecore Biomedical by 301.7% in the third quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after acquiring an additional 22,489 shares during the period. Finally, Jane Street Group LLC grew its position in Lifecore Biomedical by 101.7% in the third quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock valued at $179,000 after acquiring an additional 18,277 shares during the period. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Lifecore Biomedical

In other news, CEO Paul Josephs bought 17,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was acquired at an average price of $5.74 per share, with a total value of $97,580.00. Following the acquisition, the chief executive officer now directly owns 559,717 shares in the company, valued at approximately $3,212,775.58. This trade represents a 3.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 32.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Stephens reissued an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd. Craig Hallum increased their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 22nd.

Lifecore Biomedical Stock Up 0.5 %

NASDAQ:LFCR opened at $6.18 on Friday. The firm has a market capitalization of $228.81 million, a price-to-earnings ratio of -11.04 and a beta of 0.96. Lifecore Biomedical, Inc. has a twelve month low of $3.68 and a twelve month high of $8.01. The stock’s 50 day moving average price is $6.17 and its two-hundred day moving average price is $6.02. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21.

Lifecore Biomedical (NASDAQ:LFCR) last issued its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. Equities research analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.